Well Health to spin out and publicly list pure-play software business on TSXV
Wellstar Health SystemCompany
Well Health will spin out its Wellstar software subsidiary, merge it with a BC shell and list the pure‑play SaaS business on the TSX Venture Exchange, raising CAD$50 million (US$36.5 million) in a private placement while retaining a controlling stake.
Well Health announced on July 7, 2026 that it will spin out its Wellstar software subsidiary and list the pure‑play SaaS business on the TSX Venture Exchange, raising CAD$50 million (US$36.5 million) in a private placement. The transaction separates the digital‑health platform from the company’s core network of roughly 270 medical clinics across Canada, while keeping Well Health as a significant long‑term shareholder and customer of the newly listed entity.
Deal Terms
The spin‑out will combine Wellstar with a British Columbia‑based shell company, which will then apply for a TSXV listing. A private placement priced at $10 per subscription receipt will generate CAD$50 million, to be converted into ordinary shares once the deal closes. The closing is slated for September 2026, subject to preliminary TSXV approval. Well Health will retain a controlling equity position, ensuring strategic alignment with its clinic operations and continued access to Wellstar’s technology stack.
Background
Well Health, a Vancouver‑based clinic network and health‑tech operator, has been building its software capabilities for more than two years. The subsidiary has already raised over $100 million across two equity financings and completed two acquisitions of Canadian medical‑billing firms to broaden its service offering. Those moves were intended to load Wellstar with assets and cash in preparation for a stand‑alone public listing, a plan first floated in the company’s Q2 2024 earnings call.
The spin‑out creates a dedicated capital structure for Wellstar, giving it direct access to public‑market funding and greater visibility among investors focused on health‑tech SaaS. It also isolates the software business from the operational risks of the clinic network, allowing each entity to pursue growth strategies that are more closely aligned with its own revenue model.
By listing on the TSXV, Wellstar joins a growing cohort of Canadian digital‑health platforms that are leveraging the exchange’s lighter regulatory regime to raise growth capital quickly. The transaction is expected to fund AI‑driven product development, further organic expansion, and additional strategic acquisitions.
Why It Matters
For Well Health, the spin‑out unlocks value that the market has historically assigned to its combined clinic‑software model, allowing the parent to focus on scaling its physical‑care footprint while still benefiting from Wellstar’s technology through a controlling stake. Competitors in the Canadian health‑tech space, such as Telus Health and Maple, now face a more capital‑rich, publicly visible rival that can accelerate AI initiatives and broaden its billing platform faster than a privately held unit could.
Wellstar’s independent status also changes the dynamics of its vendor relationships. As a listed company, it can offer equity‑based incentives to attract top SaaS talent and negotiate more favorable terms with third‑party providers. Existing customers—largely Well Health’s clinic network—gain a clearer governance structure, while potential new clients see a dedicated, transparent SaaS partner rather than a subsidiary tied to a clinic operator.
Key Points
- Well Health will spin out its Wellstar software subsidiary and list it on the TSX Venture Exchange
- The transaction includes a CAD$50 million private placement priced at $10 per subscription receipt
- The spin‑out is expected to close in September 2026, pending TSXV listing approval
- Well Health will retain a controlling shareholder position in the newly listed Wellstar
- The deal values the transaction at US$36.5 million (CAD$50 million)
Analysis
The CAD$50 million raise values the newly listed Wellstar at roughly a 5‑to‑6‑times multiple of its projected annual recurring revenue, a range that aligns with recent Canadian health‑tech IPOs but is modest compared with U.S. SaaS valuations. By moving to the TSXV, Wellstar gains access to a capital market that favors high‑growth, niche software businesses, allowing it to fund AI‑driven product enhancements without diluting the parent’s balance sheet. The spin‑out reflects a broader trend of integrated health‑care operators carving out pure‑play SaaS units to unlock valuation premiums and attract investors focused on recurring‑revenue models. For operators, the structure offers a playbook: build a robust technology platform within a larger service business, then separate it once scale and product differentiation are achieved. Investors can now assess Wellstar on SaaS metrics—net revenue retention, gross margin, and ARR growth—independent of clinic performance, potentially leading to a clearer pricing multiple. The transaction also signals that Canadian capital markets remain receptive to health‑tech ventures that combine AI innovation with proven billing and practice‑management solutions, encouraging other operators to consider similar carve‑outs as a path to liquidity and growth capital.